How much revenue did Novavax generate this year?
Novavax has achieved a revenue of 1.02 B USD this year.
Novavax Revenue 2024
Novavax Revenue
1.02 B USD
Ticker
NVAX
ISIN
US6700024010
WKN
A2PKMZ
In 2024, Novavax's sales reached 1.02 B USD, a 3.18% difference from the 983.71 M USD sales recorded in the previous year.
The Novavax Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 1.21 | 52,93 |
| 2028e | 0.87 | 73,29 |
| 2027e | 0.62 | 103,67 |
| 2026e | 0.41 | 154,53 |
| 2025e | 0.43 | 148,52 |
| 2024e | 1.02 | 63,10 |
| 2023 | 0.98 | 65,10 |
| 2022 | 1.98 | 54,45 |
| 2021 | 1.15 | 55,87 |
| 2020 | 0.48 | 134,66 |
| 2019 | 0.02 | 3424,80 |
| 2018 | 0.03 | 1867,16 |
| 2017 | 0.03 | 2052,68 |
| 2016 | 0.02 | 4158,68 |
| 2015 | 0.04 | 1764,29 |
| 2014 | 0.03 | 51,14 |
| 2013 | 0.02 | 60,77 |
| 2012 | 0.02 | 33,48 |
| 2011 | 0.01 | 52,38 |
| 2010 | 0 | 100,00 |
| 2009 | 0 | 213479,00 |
| 2008 | 0 | 58221,55 |
| 2007 | 0 | 42695,80 |
| 2006 | 0 | 88,24 |
| 2005 | 0.01 | 92,45 |
| 2004 | 0.01 | 57,83 |
Novavax Revenue, EBIT, Net Income US6700024010 · A2PKMZ
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Novavax, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Novavax from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Novavax’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Novavax. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Novavax’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Novavax’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Novavax’s growth potential.
Novavax Revenue, Profit, and EBIT History
| Date | Novavax Revenue | Novavax EBIT | Novavax Net Income |
|---|---|---|---|
| 2029e | 1.21 B undefined | 0 undefined | 218.42 M undefined |
| 2028e | 873.87 M undefined | 340.34 M undefined | 80.92 M undefined |
| 2027e | 617.78 M undefined | 147.9 M undefined | 22.92 M undefined |
| 2026e | 414.45 M undefined | -101.77 M undefined | 1.07 M undefined |
| 2025e | 431.2 M undefined | -119.75 M undefined | -108.28 M undefined |
| 2024e | 1.02 B undefined | 21.51 M undefined | 68.75 M undefined |
| 2023 | 983.71 M undefined | -552.21 M undefined | -545.06 M undefined |
| 2022 | 1.98 B undefined | -644.7 M undefined | -657.9 M undefined |
| 2021 | 1.15 B undefined | -1.69 B undefined | -1.74 B undefined |
| 2020 | 475.6 M undefined | -416.7 M undefined | -418.3 M undefined |
| 2019 | 18.7 M undefined | -129.6 M undefined | -132.7 M undefined |
| 2018 | 34.3 M undefined | -173.9 M undefined | -184.7 M undefined |
| 2017 | 31.2 M undefined | -171.7 M undefined | -183.8 M undefined |
| 2016 | 15.4 M undefined | -269.1 M undefined | -280 M undefined |
| 2015 | 36.3 M undefined | -157.2 M undefined | -156.9 M undefined |
| 2014 | 30.7 M undefined | -83.7 M undefined | -82.9 M undefined |
| 2013 | 20.9 M undefined | -52.4 M undefined | -52 M undefined |
| 2012 | 22.1 M undefined | -29.7 M undefined | -28.5 M undefined |
| 2011 | 14.7 M undefined | -21.6 M undefined | -19.4 M undefined |
| 2010 | 300,000 undefined | -38.5 M undefined | -35.7 M undefined |
| 2009 | 300,000 undefined | -37.4 M undefined | -40.3 M undefined |
| 2008 | 1.1 M undefined | -34.4 M undefined | -34.5 M undefined |
| 2007 | 1.5 M undefined | -30.3 M undefined | -34.8 M undefined |
| 2006 | 1.7 M undefined | -21.1 M undefined | -23.1 M undefined |
| 2005 | 5.3 M undefined | -15.2 M undefined | -11.2 M undefined |
| 2004 | 8.3 M undefined | -34.9 M undefined | -25.9 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 8.3 M USD | -34.9 M USD | -25.9 M USD |
| 2005 | 5.3 M USD | -15.2 M USD | -11.2 M USD |
| 2006 | 1.7 M USD | -21.1 M USD | -23.1 M USD |
| 2007 | 1.5 M USD | -30.3 M USD | -34.8 M USD |
| 2008 | 1.1 M USD | -34.4 M USD | -34.5 M USD |
| 2009 | 300,000 USD | -37.4 M USD | -40.3 M USD |
| 2010 | 300,000 USD | -38.5 M USD | -35.7 M USD |
| 2011 | 14.7 M USD | -21.6 M USD | -19.4 M USD |
| 2012 | 22.1 M USD | -29.7 M USD | -28.5 M USD |
| 2013 | 20.9 M USD | -52.4 M USD | -52 M USD |
| 2014 | 30.7 M USD | -83.7 M USD | -82.9 M USD |
| 2015 | 36.3 M USD | -157.2 M USD | -156.9 M USD |
| 2016 | 15.4 M USD | -269.1 M USD | -280 M USD |
| 2017 | 31.2 M USD | -171.7 M USD | -183.8 M USD |
| 2018 | 34.3 M USD | -173.9 M USD | -184.7 M USD |
| 2019 | 18.7 M USD | -129.6 M USD | -132.7 M USD |
| 2020 | 475.6 M USD | -416.7 M USD | -418.3 M USD |
| 2021 | 1.15 B USD | -1.69 B USD | -1.74 B USD |
| 2022 | 1.98 B USD | -644.7 M USD | -657.9 M USD |
| 2023 | 983.71 M USD | -552.21 M USD | -545.06 M USD |
| 2024e | 1.02 B USD | 21.51 M USD | 68.75 M USD |
| 2025e | 431.2 M USD | -119.75 M USD | -108.28 M USD |
| 2026e | 414.45 M USD | -101.77 M USD | 1.07 M USD |
| 2027e | 617.78 M USD | 147.9 M USD | 22.92 M USD |
| 2028e | 873.87 M USD | 340.34 M USD | 80.92 M USD |
| 2029e | 1.21 B USD | 0 USD | 218.42 M USD |
Novavax stock margins US6700024010 · A2PKMZ
The Novavax margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Novavax. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Novavax.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Novavax's sales revenue. A higher gross margin percentage indicates that the Novavax retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Novavax's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Novavax's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Novavax's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Novavax. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Novavax's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Novavax Margin History
| Novavax Gross margin | Novavax Profit margin | Novavax EBIT margin | Novavax Profit margin |
|---|---|---|---|
| 2029e | 65.1 % | 0 % | 18.05 % |
| 2028e | 65.1 % | 38.95 % | 9.26 % |
| 2027e | 65.1 % | 23.94 % | 3.71 % |
| 2026e | 65.1 % | -24.55 % | 0.26 % |
| 2025e | 65.1 % | -27.77 % | -25.11 % |
| 2024e | 65.1 % | 2.12 % | 6.77 % |
| 2023 | 65.1 % | -56.14 % | -55.41 % |
| 2022 | 54.45 % | -32.53 % | -33.2 % |
| 2021 | 65.1 % | -147.13 % | -152.12 % |
| 2020 | 65.1 % | -87.62 % | -87.95 % |
| 2019 | 65.1 % | -693.05 % | -709.63 % |
| 2018 | 65.1 % | -507 % | -538.48 % |
| 2017 | 65.1 % | -550.32 % | -589.1 % |
| 2016 | 65.1 % | -1,747.4 % | -1,818.18 % |
| 2015 | 65.1 % | -433.06 % | -432.23 % |
| 2014 | 51.14 % | -272.64 % | -270.03 % |
| 2013 | 60.77 % | -250.72 % | -248.8 % |
| 2012 | 33.48 % | -134.39 % | -128.96 % |
| 2011 | 52.38 % | -146.94 % | -131.97 % |
| 2010 | 100 % | -12,833.33 % | -11,900 % |
| 2009 | 65.1 % | -12,466.67 % | -13,433.33 % |
| 2008 | 65.1 % | -3,127.27 % | -3,136.36 % |
| 2007 | 65.1 % | -2,020 % | -2,320 % |
| 2006 | 88.24 % | -1,241.18 % | -1,358.82 % |
| 2005 | 92.45 % | -286.79 % | -211.32 % |
| 2004 | 57.83 % | -420.48 % | -312.05 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 57.83 % | -420.48 % | -312.05 % |
| 2005 | 92.45 % | -286.79 % | -211.32 % |
| 2006 | 88.24 % | -1,241.18 % | -1,358.82 % |
| 2007 | 65.1 % | -2,020 % | -2,320 % |
| 2008 | 65.1 % | -3,127.27 % | -3,136.36 % |
| 2009 | 65.1 % | -12,466.67 % | -13,433.33 % |
| 2010 | 100 % | -12,833.33 % | -11,900 % |
| 2011 | 52.38 % | -146.94 % | -131.97 % |
| 2012 | 33.48 % | -134.39 % | -128.96 % |
| 2013 | 60.77 % | -250.72 % | -248.8 % |
| 2014 | 51.14 % | -272.64 % | -270.03 % |
| 2015 | 65.1 % | -433.06 % | -432.23 % |
| 2016 | 65.1 % | -1,747.4 % | -1,818.18 % |
| 2017 | 65.1 % | -550.32 % | -589.1 % |
| 2018 | 65.1 % | -507 % | -538.48 % |
| 2019 | 65.1 % | -693.05 % | -709.63 % |
| 2020 | 65.1 % | -87.62 % | -87.95 % |
| 2021 | 65.1 % | -147.13 % | -152.12 % |
| 2022 | 54.45 % | -32.53 % | -33.2 % |
| 2023 | 65.1 % | -56.14 % | -55.41 % |
| 2024e | 65.1 % | 2.12 % | 6.77 % |
| 2025e | 65.1 % | -27.77 % | -25.11 % |
| 2026e | 65.1 % | -24.55 % | 0.26 % |
| 2027e | 65.1 % | 23.94 % | 3.71 % |
| 2028e | 65.1 % | 38.95 % | 9.26 % |
| 2029e | 65.1 % | 0 % | 18.05 % |
Novavax Aktienanalyse
What does Novavax do?
Novavax Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines and products for the treatment of infectious diseases. The company was founded in 1987 in Maryland, USA, and has since relocated its headquarters to Gaithersburg, Maryland. Novavax is a pioneer in vaccine technology. The company's business model is based on the development of vaccines for diseases such as malaria, Zika, RSV, and COVID-19. Novavax uses the latest technology and methods to ensure the highest efficacy and safety of its vaccines. By licensing its own technologies and licenses, the company has significantly increased its reach and effectiveness, establishing successful partnerships with institutions such as the Bill and Melinda Gates Foundation and the US Department of Defense. The different divisions of the company are focused on the development of vaccines and antiviral therapies. Novavax is involved in clinical development and has a portfolio of vaccine candidates targeting T-cells and antibodies. Currently, Novavax is conducting studies in the field of Respiratory Syncytial Virus (RSV) vaccination. The RSV program is Novavax's oldest program, launched in 1995, and the company has developed several vaccine candidates. A recent Phase III trial of an RSV vaccine candidate for the prevention of RSV infections in pregnant women did not meet its goals. However, it is a key position in vaccine development, allowing the company to focus on the development of vaccines against other infectious diseases. Novavax also has an ongoing research program focused on developing a COVID-19 vaccine candidate based on a protein called Nanoparticle Spike Protein (NVX-CoV2373) expressed in insect cells. A major advantage of this program is that it allows for faster manufacture of millions of doses with high throughput and has consistently shown positive results in clinical studies. The company has also developed a revolutionary technology called Matrix-M, which is used in its vaccines to enhance the immune response and activity against the vaccine. It is an adjuvant technology that stimulates the body to respond to a vaccine and achieve higher immunity against the pathogen. Novavax has a number of vaccine candidates in clinical development, including vaccines against malaria, influenza, and human papillomavirus (HPV), as well as an antiviral therapy for the treatment of RSV. These programs are still in the early stages of development, but the company is confident that it will be successful in the future. Overall, Novavax is a company specializing in the development of innovative vaccines and antiviral therapies for the treatment of infectious diseases. With a focus on safety, efficacy, and innovation, the company has achieved a leading position in vaccine technology and has become a key player in the global health landscape. Answer: Novavax is a biopharmaceutical company that specializes in developing and marketing innovative vaccines and products for treating infectious diseases. It was founded in 1987 in Maryland, USA, and focuses on developing vaccines against diseases like malaria, Zika, RSV, and COVID-19. The company uses advanced technology and methods to ensure the effectiveness and safety of its vaccines. It has partnerships with institutions like the Bill and Melinda Gates Foundation and the US Department of Defense. Novavax is also involved in clinical development and has a portfolio of vaccine candidates targeting T-cells and antibodies. Its oldest program is focused on developing an RSV vaccine, and it also has a program focused on developing a COVID-19 vaccine. Novavax has developed a technology called Matrix-M, which enhances the immune response to vaccines. It also has vaccine candidates in development for malaria, influenza, and HPV, as well as an antiviral therapy for RSV. Overall, Novavax is a leading company in vaccine technology and aims to develop effective and innovative vaccines and antiviral therapies for infectious diseases. Novavax ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Novavax's Sales Figures
The sales figures of Novavax originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Novavax’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Novavax's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Novavax’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Novavax Stock
How much was the turnover of the company Novavax compared to the previous year?
The revenue of Novavax has increased by 3.18% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Novavax?
The revenue of Novavax is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Novavax measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Novavax so important for investors?
The revenue of Novavax is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Novavax pay?
Over the past 12 months, Novavax paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Novavax is expected to pay a dividend of 0 USD.
What is the dividend yield of Novavax?
The current dividend yield of Novavax is .
When does Novavax pay dividends?
Novavax pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Novavax?
Novavax paid dividends every year for the past 0 years.
What is the dividend of Novavax?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Novavax located?
Novavax is assigned to the 'Health' sector.
Wann musste ich die Aktien von Novavax kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Novavax from 6/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/26/2024.
When did Novavax pay the last dividend?
The last dividend was paid out on 6/26/2024.
What was the dividend of Novavax in the year 2023?
In the year 2023, Novavax distributed 0 USD as dividends.
In which currency does Novavax pay out the dividend?
The dividends of Novavax are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Novavax stock can be added to a savings plan with the following providers: Trade Republic and Scalable Capital
Andere Kennzahlen von Novavax
Our stock analysis for Novavax Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novavax Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
